ArticleThe oncologist2021
Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3-TACC3 Fusion and Recurrent Glioblastoma.
Article in The oncologist, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04004975 (Phase II Clinical Trials on Anlotinib for the Treatment of Recurrent Glioblastoma.), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Clinical Trials on Anlotinib for the Treatment of Recurrent Glioblastoma.
Who cites it
30 citing papers in PubMed, 41 citations in OpenAlex.
- Primary leiomyosarcoma of the lumbar soft tissue treated with multimodal therapy, including anlotinib: A case report.Oncology letters · 2026Article
- Efficacy of Anlotinib in Treating Progressive Glioblastoma: Insights From a Single-Center Study.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- A retrospective study of 30 cases evaluating the efficacy and safety of anlotinib plus Temozolomide for recurrent/residual glioma from a single center.BMC cancer · 2025Article
- Current evidence and challenges of multitarget anti-angiogenic agents for glioblastoma: Results from clinical trials.iScience · 2025Review
- FGFR inhibition as a new therapeutic strategy to sensitize glioblastoma stem cells to tumor treating fields.Cell death discovery · 2025Article
- FGFR3::TACC3 fusions in head and neck carcinomas: a study of nine cases highlighting phenotypic heterogeneity, frequent HPV association, and a morphologically distinct subset in favor of a putative entity.Virchows Archiv : an international journal of pathology · 2025Article
- Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review.Experimental hematology & oncology · 2024Review
- RT-PCR assay to detectNeuro-oncology practice · 2024Article
- Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks.Journal of experimental & clinical cancer research : CR · 2024Review
- Case report: a case of lung squamous cell carcinoma with a novel FGFR3-IER5L fusion mutation responding to anlotinib.Frontiers in oncology · 2024Article
- RNA fusion transcript panel identifies diverse repertoire of fusions in adult glioma patients with therapeutic implications.Neuro-oncology practice · 2023Article
- Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation.The oncologist · 2023Article
- Molecular targeted therapy: A new avenue in glioblastoma treatment.Oncology letters · 2023Review
- Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion.Acta neuropathologica communications · 2023Article
- Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications.Cancer biomarkers : section A of Disease markers · 2023Review
- FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma.International journal of molecular sciences · 2022Review
- Safety and Efficacy of Hypofractionated Stereotactic Radiotherapy with Anlotinib Targeted Therapy for Glioblastoma at the First Recurrence: A Preliminary Report.Brain sciences · 2022Article
- Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway.Cancer chemotherapy and pharmacology · 2022Article
- Identification and Verification of an Alternative Polyadenylation-Related lncRNA Prognostic Signature for Glioma.Computational and mathematical methods in medicine · 2022Article
- Case Report: Targeted Therapy with Anlotinib for a Rare Case of Spinal Cord Glioblastoma withOncoTargets and therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe a case of recurrent glioblastoma treated with anlotinib in this report. The patient was administered anlotinib 12 mg p.o. once every day (days 1-14, with a 21-day cycle) (anlotinib clinical study NCT04004975) and oral temozolomide chemotherapy 100 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.